• About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
Menu
  • About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
ebola
JOIN
Posted on July 2, 2024July 2, 2024

Request for Review: Vaccine Safety Template for Clover COVID-19 recombinant protein vaccine

The proposed Clover COVID-19 recombinant protein vaccine manuscript is ready for peer review. The Brighton Collaboration BRAVATO (...
Read More
Posted on May 30, 2024May 30, 2024

Ensuring the safety of dengue vaccines: Alejandro Cravioto brings international expertise to the Pan-American Advisory Committee on Vaccine Safety

The World Health Organization (WHO) has reported a ten-fold increase in dengue cases over the past twenty years. Today, nearly 4 b...
Read More
Posted on March 22, 2024March 22, 2024

Dr. Eileen Farnon joins Brighton Collaboration as Research Director

The Task Force for Global Health welcomes Dr. Eileen Farnon as Brighton Collaboration’s new Research Director. Dr. Farnon, w...
Read More
Posted on March 11, 2024March 15, 2024

Lessons Learned and Key Recommendations from the COVAX Vaccine Safety Working Group

The Vaccine Safety Working Group (VSWG) of COVAX was formed in November 2020 with representatives and consultants representing mul...
Read More
Posted on February 21, 2024April 15, 2024

COVID-19 Safety Studies project offers evidence to support increasing active vaccine safety surveillance in low- and middle-income countries

Vaccine safety data can help build public confidence in vaccines by communicating that the benefits outweigh the risks of immuniza...
Read More
Posted on February 19, 2024February 21, 2024

99 Million People Included in Largest Global Vaccine Safety Study

Global Vaccine Data Network utilises vast data sets to detect potential vaccine safety signals 19 February 2024—The Global Vacc...
Read More
Posted on February 5, 2024

Request for Review: Standardized template with key considerations for a benefit/risk assessment for the Comirnaty COVID-19 mRNA vaccine

The proposed mRNA BioNTech/Comirnaty manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Asses...
Read More
Posted on January 17, 2024January 31, 2024

New University of Alberta-based study to examine very rare adverse events linked to COVID-19 vaccines

The multimillion-dollar global initiative will study causes and risk factors, to ensure safer vaccines are ready for the next pote...
Read More
Posted on November 9, 2023January 3, 2024

SPEAC’s Real-World Evidence Framework

This editorial by Dr. Robert T. Chen first appeared in the October 2023 issue of Safety by Numbers. It is reposted here with per...
Read More
Posted on October 31, 2023November 20, 2023

Request for Review: TTS-VITT Draft Brighton Case Definition

Dear Brighton Collaboration members: Please find below a draft Brighton Collaboration case definition for both TTS (thrombosis...
Read More
Previous page 1 2 3 4 5 Next page

Recent Posts

  • Fetal VacciniaAugust 10, 2026
  • Acute Intraocular InflammationJuly 1, 2026
  • Acute Multi-Organ DysfunctionJune 2, 2026
  • WHO Resource References Brighton Collaboration StandardsMay 11, 2026
  • Request for Review: Acute Multi-Organ Dysfunction (aMOD) Brighton Case DefinitionFebruary 4, 2026

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

  • Case Definitions
  • Safety Templates
  • Covid-19
  • Trusted Sources
Linkedin

© Brighton Collaboration  2023. All rights reserved.

  • Disclaimer and Privacy Policy